AstraZeneca seals $630M move to own China rights for CAR-T therapy C-CAR031
AstraZeneca will pay up to $630 million to acquire the remaining China rights to its GPC3-targeting CAR-T therapy C-CAR031, giving it full global rights; the deal follows a prior China arrangement and aligns with AZ's push to develop CAR-T therapies for hepatocellular carcinoma, which showed promising early responses in China.